Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Exclusion Criteria

• •1. Any acute disease or condition being treated by medical therapy (prescription or over the counter) known to possibly impact hepatic function
• •2. History of or recent (\< 6 weeks) treatment for a chronic condition with a medication that is known to have hepatotoxic potential.
• •3. Any significant physical injury or surgical procedure within 6 weeks of Screening
• •4. Uncontrolled diabetes (hemoglobin A1c \[HbA1c\] \> 9.5%)
• •5. Uncontrolled hypertension (systolic blood pressure \[SBP\] \> 180 mmHg on ≥ 3 medications of different classes for blood pressure control)
• •6. Have received any investigational medication within 30 days or 5 half-lives, whichever is longer, prior to study dosing
• •7. Subjects should not have donated blood within 60 days of study entry or plasma within 7 days of study entry. Subjects must also refrain from blood donation from clinic admission, throughout the study period, and continuing for at least 30 days following the last dose of study medication.
• •8. Positive urine drug screen at Screening that is not otherwise explained by a permitted concomitant medication
• •9. History of alcoholism in the 6 months prior to Screening
• •10. Inadequate peripheral venous access